Innovative Health Diagnostics (IHD)
IHD was created in October 2008 in Strasbourg by Xavier Regnaut, Dr Jean
de Barry and Dr François Sellal. The company is dedicated to developing
diagnostic tests for Alzheimer's disease and neurodegenerative diseases. The
French National Centre for Scientific Research the CNRS granted IHD two
exclusive world licences for their patents portfolio which now number 5.
IHD participates in the European research programme PharmaCOG. IHD is
presently developing two complementary blood tests: a specific test the
IHD-Amy and a sensitive test the IHD-PKC developed in vivo on animal models
for Alzheimer's disease.
The markets being targeted by IHD are primarily
the pre-clinical and clinical development of therapeutic agents, also the
therapeutic monitoring of patients, and the initial diagnosis and screening
of the disease.
Innovative Health Diagnostics
Centre de Neurochimie
5, rue Blaise
67084 Strasbourg Cedex